Literature DB >> 12847679

Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.

Mihai G Netea1, Timothy Radstake, Leo A Joosten, Jos W M van der Meer, Pilar Barrera, Bart Jan Kullberg.   

Abstract

OBJECTIVE: Patients treated with antibodies to tumor necrosis factor alpha (TNFalpha) have an increased susceptibility to intracellular infections. We describe 2 patients with rheumatoid arthritis (RA) who developed Salmonella septicemia during anti-TNF treatment. The aim of this study was to identify the mechanisms involved in the increased susceptibility of anti-TNF-treated patients to intracellular microorganisms.
METHODS: We evaluated an additional 6 RA patients receiving anti-TNF antibodies, 5 RA patients not receiving anti-TNF therapy, and 6 age- and sex-matched healthy volunteers. The in vitro production of cytokines (interleukin-1beta [IL-1beta], IL-6, interferon-gamma [IFNgamma], and IL-10) upon bacterial stimulation of whole blood and the expression of Toll-like receptor 4 (TLR-4) on dendritic cells from RA patients treated with infliximab, RA patients not treated with infliximab, and healthy controls were compared.
RESULTS: Stimulation with heat-killed Salmonella typhimurium or Candida albicans led to a significantly decreased production of IFNgamma, but not to a decreased production of IL-10, IL-beta, or IL-6, in anti-TNF-treated RA patients compared with RA patients who were not receiving anti-TNF antibodies and compared with healthy controls. TNF-blocking treatment ex vivo significantly inhibited TLR-4 expression on dendritic cells from RA patients and healthy controls.
CONCLUSION: Since recognition of microorganisms by TLR-4 and activation of phagocytes by IFNgamma are essential mechanisms for the defense against intracellular and fungal pathogens, we propose that this pathway is crucial for the increased susceptibility to these microorganisms in patients receiving anti-TNF therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847679     DOI: 10.1002/art.11151

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  21 in total

Review 1.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 2.  Pathogenesis of spondyloarthritis: insights from synovial membrane studies.

Authors:  Leen De Rycke; Elli Kruithof; Bernard Vandooren; Paul P Tak; Dominique Baeten
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

3.  Listeriosis in patients receiving biologic therapies.

Authors:  M Bodro; D L Paterson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-09       Impact factor: 3.267

4.  Granulomatous salmonella osteomyelitis associated with anti-tumor necrosis factor therapy in a non-sickle cell patient: a case report.

Authors:  Elaine S Gould; Anthony G Gilet; Vincent J Vigorita
Journal:  Skeletal Radiol       Date:  2010-02-21       Impact factor: 2.199

Review 5.  Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

Authors:  Filip De Keyser; Dominique Baeten; Filip Van den Bosch; Elli Kruithof; Gust Verbruggen; Herman Mielants; Eric Veys
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  How tumour necrosis factor blockers interfere with tuberculosis immunity.

Authors:  J Harris; J Keane
Journal:  Clin Exp Immunol       Date:  2010-05-18       Impact factor: 4.330

7.  Complicated Whipple's disease and endocarditis following tumor necrosis factor inhibitors.

Authors:  Thomas Marth
Journal:  World J Cardiol       Date:  2014-12-26

8.  Cavitating pneumonia after treatment with infliximab and prednisone.

Authors:  S M Arend; E J Kuijper; C F Allaart; W Hissink Muller; J T Van Dissel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-23       Impact factor: 3.267

Review 9.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

10.  Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.

Authors:  Brent W Kinder; Michelle M Freemer; Talmadge E King; Raymond F Lum; Joanne Nititham; Kim Taylor; Jeffrey C Edberg; S Louis Bridges; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.